Literature DB >> 23875638

Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.

Vinod H Gupta1, Deepak N Amarapurkar, Meenakshi Singh, Preetha Sasi, Jyotsna M Joshi, Rajiv Baijal, Praveenkumar H Ramegowda, Anjali D Amarapurkar, Kalpana Joshi, Pramod P Wangikar.   

Abstract

BACKGROUND AND AIM: Tuberculosis (TB) is a major public health problem in India. Despite the treatment availability and monitoring, drug-induced hepatotoxicity (DIH) is a serious concern and can lead to discontinuation of treatment. Anti-TB DIH is well known and can aggravate because of pharmacokinetic and pharmacodynamic interactions. Genetic polymorphism in the drug-metabolizing enzyme genes is an important factor that predisposes certain fraction of the population to drug-induced toxicity. The purpose of this study was to assess the association of N-acetyltransferase 2 (NAT2) and cytochrome P450 2E1 (CYP2E1) gene polymorphism with anti-TB DIH in Western Indian population.
METHODS: A prospective cohort study of 215 patients taking treatment against TB was performed. The NAT2 and CYP2E1 genotypes were determined using polymerase chain reaction and restriction fragment length polymorphism methods. Logistic regression model was used to calculate odds ratio at 95% confidence interval and their respective P values.
RESULTS: The risk of anti-TB DIH was significantly higher in slow acetylator (SA) than in intermediate and rapid acetylator of NAT2 genotypes (odds ratio: 2.3, P = 0.01). We also observed the homozygous point mutation at position 481, associated with higher risk of hepatotoxicity (P < 0.01). The major haplotype NAT2*4 seems to provide protection in DIH compared with non-DIH TB patients (P = 0.04). However, we did not find a significant association between CYP2E1 genotypes and anti-TB DIH.
CONCLUSION: Increased susceptibility to isoniazid (INH)-induced hepatotoxicity due to presence of NAT2 SA polymorphism was demonstrated in Western Indian population. NAT2 genotyping can therefore serve as an important tool for identifying patients predisposed to anti-TB DIH.
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  TB patients; drug-induced hepatotoxicity; genetic polymorphisms; slow acetylator

Mesh:

Substances:

Year:  2013        PMID: 23875638     DOI: 10.1111/jgh.12194

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  18 in total

1.  Role of CYP3A in isoniazid metabolism in vivo.

Authors:  Ke Liu; Feng Li; Jie Lu; Zhiwei Gao; Curtis D Klaassen; Xiaochao Ma
Journal:  Drug Metab Pharmacokinet       Date:  2013-10-29       Impact factor: 3.614

2.  PharmGKB summary: isoniazid pathway, pharmacokinetics.

Authors:  Daniel J Klein; Sotiria Boukouvala; Ellen M McDonagh; Scott R Shuldiner; Nicola Laurieri; Caroline F Thorn; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2016-09       Impact factor: 2.089

3.  NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis.

Authors:  M Richardson; J Kirkham; K Dwan; D J Sloan; G Davies; A L Jorgensen
Journal:  Int J Tuberc Lung Dis       Date:  2019-03-01       Impact factor: 2.373

Review 4.  PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.

Authors:  Ellen M McDonagh; Sotiria Boukouvala; Eleni Aklillu; David W Hein; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-08       Impact factor: 2.089

5.  A framework and case studies for evaluation of enzyme ontogeny in children's health risk evaluation.

Authors:  Gary Ginsberg; Suryanarayana V Vulimiri; Yu-Sheng Lin; Jayaram Kancherla; Brenda Foos; Babasaheb Sonawane
Journal:  J Toxicol Environ Health A       Date:  2017-09-11

6.  Deficiency of N-acetyltransferase increases the interactions of isoniazid with endobiotics in mouse liver.

Authors:  Pengcheng Wang; Amina I Shehu; Jie Lu; Rujuta H Joshi; Raman Venkataramanan; Kim S Sugamori; Denis M Grant; Xiao-Bo Zhong; Xiaochao Ma
Journal:  Biochem Pharmacol       Date:  2017-09-06       Impact factor: 5.858

7.  Clinical and Molecular Risk Factors of Anti-tubercular Therapy Induced Hepatitis.

Authors:  Premashis Kar; Rahul Karna; Rajesh Ruttala; Shilpa Arora; Anita Chakravarty; Suresh Kumar
Journal:  J Clin Exp Hepatol       Date:  2018-06-21

8.  N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group.

Authors:  Ching-Soon Ng; Abul Hasnat; Abdullah Al Maruf; Maizbha Uddin Ahmed; Munir Pirmohamed; Christopher P Day; Guruprasad P Aithal; Ann K Daly
Journal:  Eur J Clin Pharmacol       Date:  2014-06-03       Impact factor: 2.953

9.  NAT2 Gene rs1041983 is Associated with Anti-Tuberculosis Drug Induced Hepatotoxicity Among Pediatric Tuberculosis in Bandung, Indonesia.

Authors:  Achmad Headriawan; Alvinsyah Adhityo Pramono; Abdurachman Sukadi; Alex Chairulfatah; Ani Melani Maskoen; Heda Melinda Nataprawira
Journal:  Appl Clin Genet       Date:  2021-06-03

Review 10.  Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.

Authors:  E Sim; A Abuhammad; A Ryan
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.